Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) on March 13, 2026 filed a patent application with Hong Kong IPD for a combination therapy pairing proprietary MEAI with Palmitoylethanolamide (PEA) to treat major depressive disorder (MDD).
The filing notes the PEA supply via a partnership with NeuroThera Labs (TSXV: NTLX), a SciSparc subsidiary, and positions the MEAI-PEA synergy as a non-hallucinogenic neuroplastogen approach targeting an MDD market projected above $25 billion by 2030.
Positive
- None.
Negative
- None.
News Market Reaction – CMND
In the Mar 13 session, CMND declined 5.88%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.9% during that session. Argus tracked a trough of -15.7% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Trial enrollment update | Positive | -6.3% | Continued enrollment for CMND-100 Cohort 3 after positive Cohort 2 data. |
| Mar 10 | Patent publication | Positive | -2.0% | International PCT patent publication for MEAI-PEA therapy targeting weight loss and MASLD. |
| Mar 4 | DSMB trial review | Positive | -4.8% | DSMB cleared CMND-100 trial to advance to third cohort with 80 mg dosing. |
| Feb 19 | Promotional overview | Positive | +4.2% | Paid media review highlighting MEAI and GLP‑1 as next‑generation weight-loss approaches. |
| Feb 9 | Safety data update | Positive | -8.2% | Additional positive safety topline results from CMND-100 second cohort in Phase I/IIa trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and IP updates have often been followed by negative next-day price moves, suggesting a pattern of selling into good news.
Over the past month, Clearmind reported multiple clinically and strategically positive developments, including DSMB approvals and additional positive safety data for its CMND-100 Phase I/IIa trial on Feb 9 and Mar 4, and continued cohort enrollment on Mar 11. It also highlighted new IP around MEAI‑PEA combinations and weight-loss applications on Mar 10. Despite these milestones, four of the last five news days saw next-day declines, framing today’s Hong Kong patent filing within a backdrop of repeated selloffs on constructive updates.
Key Terms
major depressive disorder medical
palmitoylethanolamide medical
ssris medical
neuroplastogen medical
major depressive disorder (mdd) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass
Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).
This innovative treatment blends Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced via its partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC).
The patent filing underscores the potential promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally. Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including SSRIs and other conventional options.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how the patent filing underscores the potential promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression and how the Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
